Cellectar Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 87.51. In total, the insiders bought 11 247 780 and sold 234 742 CLRB shares in the last 100 trades.

Insider Power

(Last 100 transactions)
87.51
Buy 11 247 780 Shares
Sell 234 742 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 14, 2024 Stock option (right to buy) Buy Longcor Jarrod 500 000
Jun 14, 2024 Stock option (right to buy) Buy Caruso James V 900 000
Jun 14, 2024 Stock option (right to buy) Buy Kolean Chad J 290 000
Jun 14, 2024 Stock option (right to buy) Buy Shustov Andrei 260 000
Jun 14, 2024 Stock option (right to buy) Buy Lea Darrell Shane 260 000
Jun 14, 2024 Stock option (right to buy) Buy Loren Stefan 60 000
Jun 14, 2024 Stock option (right to buy) Buy Swirsky Douglas J 90 000
Jun 14, 2024 Stock option (right to buy) Buy Neis John 60 000
Jun 14, 2024 Stock option (right to buy) Buy Driscoll Frederick W 60 000
Jun 14, 2024 Stock option (right to buy) Buy Chanan-khan Asher 60 000
Dec 08, 2023 Common Stock Buy Lea Darrell Shane 39 599
Dec 08, 2023 Common Stock Buy Kolean Chad J 42 554
Dec 08, 2023 Common Stock Buy Shustov Andrei 47 856
Dec 08, 2023 Common Stock Buy Longcor Jarrod 42 927
Dec 08, 2023 Common Stock Buy Caruso James V 40 596
Jun 28, 2023 Stock option (right to buy) Buy Swirsky Douglas J 37 500
Jun 28, 2023 Stock option (right to buy) Buy Neis John 25 000
Jun 28, 2023 Stock option (right to buy) Buy Loren Stefan 25 000
Jun 28, 2023 Stock option (right to buy) Buy Driscoll Frederick W 25 000
Jun 28, 2023 Stock option (right to buy) Buy Chanan-khan Asher 25 000
Jun 23, 2023 Stock option (right to buy) Buy Lea Darrell Shane 100 000
Jun 23, 2023 Stock option (right to buy) Buy Kolean Chad J 104 000
Jun 23, 2023 Stock option (right to buy) Buy Longcor Jarrod 144 000
Jun 23, 2023 Stock option (right to buy) Buy Caruso James V 261 000
Feb 15, 2023 Stock option (right to buy) Buy Shustov Andrei 100 000
Click to get the best stock tips daily for free!

About Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients;... CLRB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT